The SARS-COVID 19 pandemic is a scientific, medical and social challenge. The complexity of the virus is centred on the unpredictable clinical course of the disease that can rapidly develop, causing severe and deadly complications. The identification of effective laboratory biomarkers able to classify patients based on their risk is imperative in being able to guarantee prompt treatment. The analysis of recently published studies highlights the role of systemic vasculitis and cytokine mediated coagulation disorders as the principal actors of multi organ failure in patients with severe COVID-19 complications. The following biomarkers have been identified: haematological (lymphocyte count, neutrophil count, neutrophil-lymphocyte-ratio (NLR), and Hhemoglobin ), inflammatory (C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), procalcitonin(PCT )), immunological (IL-6 ) and biochemical (D-Dimer, Troponin, CK, AST ), especially those related to coagulation cascades in disseminated intravascular coagulation (DIC) and acute respiratory distress syndrome (ARDS). New laboratory biomarkers could be identified through the accurate analysis of multicentric case series; in particular, homocysteine and angiotensin II could play a significant role.

Biomarkers associated with COVID-19 disease progression / Ponti, Giovanni; Maccaferri, Monia; Ruini, Cristel; Tomasi, Aldo; Ozben, Tomris. - In: CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES. - ISSN 1040-8363. - (2020), pp. 111-119. [10.1080/10408363.2020.1770685]

Biomarkers associated with COVID-19 disease progression

Giovanni Ponti
Writing – Original Draft Preparation
;
Monia Maccaferri
Data Curation
;
Cristel Ruini;Aldo Tomasi
Supervision
;
2020

Abstract

The SARS-COVID 19 pandemic is a scientific, medical and social challenge. The complexity of the virus is centred on the unpredictable clinical course of the disease that can rapidly develop, causing severe and deadly complications. The identification of effective laboratory biomarkers able to classify patients based on their risk is imperative in being able to guarantee prompt treatment. The analysis of recently published studies highlights the role of systemic vasculitis and cytokine mediated coagulation disorders as the principal actors of multi organ failure in patients with severe COVID-19 complications. The following biomarkers have been identified: haematological (lymphocyte count, neutrophil count, neutrophil-lymphocyte-ratio (NLR), and Hhemoglobin ), inflammatory (C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), procalcitonin(PCT )), immunological (IL-6 ) and biochemical (D-Dimer, Troponin, CK, AST ), especially those related to coagulation cascades in disseminated intravascular coagulation (DIC) and acute respiratory distress syndrome (ARDS). New laboratory biomarkers could be identified through the accurate analysis of multicentric case series; in particular, homocysteine and angiotensin II could play a significant role.
15-mag-2020
111
119
Biomarkers associated with COVID-19 disease progression / Ponti, Giovanni; Maccaferri, Monia; Ruini, Cristel; Tomasi, Aldo; Ozben, Tomris. - In: CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES. - ISSN 1040-8363. - (2020), pp. 111-119. [10.1080/10408363.2020.1770685]
Ponti, Giovanni; Maccaferri, Monia; Ruini, Cristel; Tomasi, Aldo; Ozben, Tomris
File in questo prodotto:
File Dimensione Formato  
lettera diinvito.pdf

non disponibili

Descrizione: Lettera di Invito
Tipologia: Altro materiale allegato
Dimensione 241.64 kB
Formato Adobe PDF
241.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1202483
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 295
  • ???jsp.display-item.citation.isi??? 292
social impact